NKTRNektar Therapeutics
$37.21-32% 1Y
$37.21
$35.1252 weeks$100.35
Is the price fair?
What NKTR's price assumes
Nektar Therapeutics did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 42.2× revenue.
42.2
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 2.55
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 2.55
- EV / EBIToperating margin −258%: the multiple describes the denominator
- not meaningful
- Market capitalisation34.1 million shares, counted Aug 7, 2026
- $1.27B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks